Attention Medical Professionals: PJSC Kraspharma has launched a new antimicrobial product — Sabvixin (Polymyxin B), now available on the market.
12.01.2018
Attention Medical Professionals: PJSC Kraspharma has launched a new antimicrobial product — Sabvixin (Polymyxin B), now available on the market.
PJSC "Kraspharma" Launches Sabvixin (Polymyxin B) — a Critical Addition in the Fight Against Multidrug-Resistant Infections
The long-anticipated launch of Sabvixin (active ingredient: Polymyxin B) by PJSC Kraspharma marks a significant advancement in the company’s antimicrobial portfolio for 2017.
In the context of the growing global threat of antimicrobial resistance, polymyxins are increasingly regarded as last-resort agents — the backbone of “salvage therapy.”
Sabvixin offers targeted activity against multidrug-resistant Gram-negative pathogens, particularly Pseudomonas aeruginosa and Acinetobacter spp., delivering effective treatment options where others fail.
Further details about Sabvixin are available via the following link >>
The long-anticipated launch of Sabvixin (active ingredient: Polymyxin B) by PJSC Kraspharma marks a significant advancement in the company’s antimicrobial portfolio for 2017.
In the context of the growing global threat of antimicrobial resistance, polymyxins are increasingly regarded as last-resort agents — the backbone of “salvage therapy.”
Sabvixin offers targeted activity against multidrug-resistant Gram-negative pathogens, particularly Pseudomonas aeruginosa and Acinetobacter spp., delivering effective treatment options where others fail.
Further details about Sabvixin are available via the following link >>
